Tue.Nov 26, 2024

article thumbnail

Top 10 Cancer Drugs to Watch in 2024 Based on Recent Sales Data

XTalks

As oncology continues to dominate the pharmaceutical market, the global demand for effective cancer therapies has reached unprecedented levels. With advances in precision medicine and immunotherapy driving innovation, leading oncology drugs are not only transforming treatment paradigms but also generating billions in revenue. The year 2023 was no exception, with several cancer drugs achieving remarkable sales milestones, reflecting their efficacy, expanding indications and the growing global can

Sales 78
article thumbnail

Stem Cells Grown in Space Turn Out to Have a Surprise Advantage

AuroBlog - Aurous Healthcare Clinical Trials blog

(SciePro/Science Photo Library/Getty Images) Stem cells are special in the way they can keep on replicating, and turn themselves into many other types of cell. Now scientists have discovered how their superpowers get a remarkable boost when they’re grown in space.

Scientist 193
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech   

Pharmaceutical Technology

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

article thumbnail

Alector turns to layoffs as Alzheimer’s drug fails

Bio Pharma Dive

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.

Drugs 157
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

November 26, 2024: Hybrid Methods Improve Collection of Patient-Reported Outcome Measures in Rural and Underserved Populations

Rethinking Clinical Trials

In an article published online this week , leaders from the NIH Pragmatic Trials Collaboratory share lessons learned about the collection of patient-reported outcome measures (PROMs) in medically underserved patients, including people with incomes below the federal poverty threshold, racial or ethnically minoritized groups, and rural and frontier communities.

Trials 147
article thumbnail

Roche to buy cell therapy developer Poseida for $1B

Bio Pharma Dive

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing share price on Monday.

More Trending

article thumbnail

Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark

Bio Pharma Dive

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.

Drugs 157
article thumbnail

Roche’s tiragolumab flops in another Phase III lung cancer trial

Pharmaceutical Technology

Tiragolumab missed the chance to prove a survival benefit in SKYSCRAPER-01 adding to previous trial failures for the anti-TIGIT therapy.

Trials 130
article thumbnail

Roche’s TIGIT-targeting drug for cancer fails its biggest test

Bio Pharma Dive

Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in a closely followed Phase 3 study called SKYSCRAPER-01.

Drugs 144
article thumbnail

Shorla Oncology’s IMKELDI approved by FDA for leukaemia cancers

Pharmaceutical Technology

The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer forms.

Drugs 130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

ICMR invites proposals for clinical studies on medical device and diagnostic technologies under CAR scheme

AuroBlog - Aurous Healthcare Clinical Trials blog

The Indian Council of Medical Research (ICMR) has announced an open call for proposals under its Centre for Advanced Research (CAR) scheme to support clinical studies for medical device and diagnostic technologies developed through the ICMR-DHR-Centre of Excellence (CoEs) programme at various IITs.

Research 111
article thumbnail

Roche to acquire Poseida Therapeutics for $1.5bn

Pharmaceutical Technology

Roche has signed an agreement for the acquisition of Poseida Therapeutics in a deal representing a total value of up to $1.5bn.

130
130
article thumbnail

Novartis plots more than 100 layoffs in New Jersey as part of rework to Xolair, cancer combo field sales teams

Fierce Pharma

While Novartis has largely wrapped up its transformation into a leaner innovative medicines company—which included multiple rounds of staff cuts over the years—employment changes are still afoot at | Novartis is laying off a total of 139 staffers in East Hanover, New Jersey, where the company’s U.S. headquarters is located. The move will primarily affect commercial field sales associates working on the brands Xolair for asthma and allergies and the oncology combo made up of kinase inhibitors Taf

Sales 111
article thumbnail

Eton acquires US rights to neonatal diabetes treatment from AMMTeK

Pharmaceutical Technology

Eton has acquired the rights in the US to Amglidia for neonatal diabetes mellitus, from French biotechnology company AMMTeK.

130
130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Intellectual Property Rights and Regulatory Considerations for Drug Repurposing

Drug Patent Watch

In the ever-evolving landscape of pharmaceutical research and development, drug repurposing has emerged as a promising strategy to bring new treatments to patients more quickly and cost-effectively. However, navigating the complex web of intellectual property rights and regulatory considerations in this field can be challenging.

Drugs 94
article thumbnail

NHS rolls out monoclonal antibody treatment for rare bone disease  

Pharmaceutical Technology

The NHS will provide the monoclonal antibody Crysvita at 20 specialist centres across England for patients with XLH.

Antibody 130
article thumbnail

BridgeBio’s Attruby (Acoramidis): A New, More Potent TTR Stabilizer for ATTR-CM

XTalks

The US Food and Drug Administration (FDA) has approved Attruby (acoramidis) , marking a significant advancement for patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction. Attruby offers a near-complete stabilization of TTR — over 90 percent — halting the formation of amyloid fibrils that cause tissue damage and addressing the underlying p

article thumbnail

Medigene axes staff and refocuses its TCR pipeline

pharmaphorum

Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline.

Trials 105
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Fast-growing Adragos snaps up Swiss CDMO Baccinex, significantly expanding fill-finish firepower

Fierce Pharma

German CDMO Adragos Pharma has been on a growth tear this year, drafting plans to boost capacity in Japan, upgrading a facility in France, taking over another from Fresenius Kabi in Norway and more | German CDMO Adragos Pharma has been on a growth tear this year. Now, the manufacturing arriviste—which was founded in 2020—is expanding its production network again with the acquisition of Switzerland's Baccinex, which specializes in fill and finish services.

article thumbnail

Roche buys off-the-shelf CAR-T player Poseida for $1bn

pharmaphorum

Roche has upgraded its partnership with off-the-shelf CAR-T therapy specialist Poseida to a $1 billion-plus takeover bid.

92
article thumbnail

Shorla gains FDA nod for first oral liquid version of Novartis' Gleevec

Fierce Pharma

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “am | Shorla Oncology has scored an FDA approval for its strawberry-flavored drink version of Novartis' cancer drug Gleevec. Dubbed Imkeldi, it becomes the first oral liquid form of imatinib.

article thumbnail

MSD adds rocket fuel to Winrevair's engine in PAH

pharmaphorum

ZENITH trial of MSD's Winrevair in PAH could add further momentum to an already impressive launch.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Shedding Some Daylight on the Murky World of Patient Recruitment Advertising Practices

ACRP blog

A sponsor representative, site representative, and an institutional review board (IRB) representative walk into a bar with a mission to solve patient recruitment challenges once and for all. Each of them orders a wildly different drink. Each of them spills most of their drink while scribbling obscure notes on bar napkins in huddled consultations with everyone but their original companions.

article thumbnail

Biden ramps up Medicare coverage of obesity drugs

pharmaphorum

Outgoing US President Joe Biden has proposed a dramatic expansion of Medicare coverage of obesity drugs, but will the plan see the light of day?

Drugs 78
article thumbnail

Gentlemen, Start Your Engines: DEA’s Marijuana Rescheduling Hearing Begins Monday

FDA Law Blog

By Larry K. Houck — Last May the Department of Justice (“DOJ”) and the Drug Enforcement Administration (“DEA”) issued a Notice of Proposed Rulemaking (“NPRM”) to transfer marijuana from schedule I of the Controlled Substances Act (“CSA”) to schedule III. Schedules of Controlled Substances: Rescheduling of Marijuana, 89 Fed. Reg. 44,597 (May 21, 2024).

article thumbnail

Transforming pharmacovigilance: The revolutionary impact of generative AI on drug safety

pharmaphorum

Discover the revolutionary impact of generative artificial intelligence (GenAI) on drug safety in pharmacovigilance. Learn how this cutting-edge technology is transforming the industry.

Drugs 59
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Beyond Data Collection: How Modern EDC Systems Are Becoming Clinical Intelligence Hubs

Crucial Data Soutions

For years, electronic data capture (EDC) systems have been the backbone of clinical trials, efficiently collecting and managing study data. The post Beyond Data Collection: How Modern EDC Systems Are Becoming Clinical Intelligence Hubs appeared first on Crucial Data Solutions.

article thumbnail

CAR-T therapies: Faster, better, cheaper

pharmaphorum

Tune in to this podcast episode featuring an interview with Phil Johnson from Interius Biotherapeutics as he discusses the latest advancements in CAR-T therapies, focusing on faster, better, and cheaper treatments.

52
article thumbnail

Ethical Considerations for AI Use in Healthcare Marketing

Intouch Solutions

The Current Landscape: AI’s Transformative Impact on Healthcare Marketing The healthcare marketing industry is at the forefront of a significant transformation, driven by advances in artificial intelligence (AI). Today, generative AI applications – particularly large language models (LLMs) and image-generation tools – are streamlining labor-intensive tasks such as research, documentation, content editing and concept ideation.

article thumbnail

How Leaders Can Foster Proactive and Reactive Change

Pharmaceutical Commerce

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, offers advice for effectively being able to adjust plans.

52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.